Loading…
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $48M | $-158M | $-170M | $-171M | 138.8% | -57.7% | 201.4% |
| 2024 | $115M | $-40M | $-57M | $-3M | -191.7% | - | -68.6% |
| 2023 | $0M | $-162M | $-180M | $-159M | -286.5% | - | -21.6% |
| 2022 | $0M | $-211M | $-229M | $-188M | -1899.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 114.70 | 48.47 |
| Operating Revenue | - | 0 | 0 | 114.70 | 48.47 |
| Operating Expense | - | 218.53 | 173.76 | 174.62 | 211.72 |
| Research And Development | - | 170.92 | 135.30 | 138.49 | 174.09 |
| Selling General And Administration | - | 47.61 | 38.46 | 36.13 | 37.63 |
| Total Expenses | - | 218.53 | 173.76 | 174.62 | 211.72 |
| Operating Income | - | -218.53 | -173.76 | -59.92 | -163.25 |
| Total Operating Income As Reported | - | -218.59 | -183.76 | -59.92 | -170.73 |
| EBITDA | - | -211.07 | -161.92 | -39.97 | -158.47 |
| Normalized EBITDA | - | -211 | -151.92 | -39.97 | -150.99 |
| EBIT | - | -215.50 | -166.31 | -44.12 | -159.47 |
| Interest Income | - | 1.58 | 2 | 1.78 | 1.97 |
| Interest Expense | - | 13.88 | 13.51 | 11.52 | 10.99 |
| Net Interest Income | - | -12.30 | -11.51 | -9.74 | -9.02 |
| Other Non Operating Income Expenses | - | 1.51 | 15.46 | 14.02 | 9.29 |
| Other Income Expense | - | 1.45 | 5.46 | 14.02 | 1.81 |
| Interest Income Non Operating | - | 1.58 | 2 | 1.78 | 1.97 |
| Interest Expense Non Operating | - | 13.88 | 13.51 | 11.52 | 10.99 |
| Net Non Operating Interest Income Expense | - | -12.30 | -11.51 | -9.74 | -9.02 |
| Pretax Income | - | -229.38 | -179.82 | -55.64 | -170.46 |
| Tax Provision | - | 0 | 0 | 0.89 | -0.09 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income From Continuing And Discontinued Operation | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income From Continuing Operation Net Minority Interest | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income Common Stockholders | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income Including Noncontrolling Interests | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Normalized Income | - | -229.31 | -169.82 | -56.53 | -162.90 |
| Diluted NI Availto Com Stockholders | - | -229.38 | -179.82 | -56.53 | -170.37 |
| Basic Average Shares | - | 84.57 | 152.62 | 226.23 | 228.52 |
| Diluted Average Shares | - | 84.57 | 152.62 | 226.23 | 228.52 |
| Reconciled Depreciation | - | 4.43 | 4.38 | 4.15 | 1 |
| Total Unusual Items | - | -0.06 | -10 | 0 | -7.48 |
| Total Unusual Items Excluding Goodwill | - | -0.06 | -10 | 0 | -7.48 |
| Special Income Charges | - | -0.06 | -10 | 0 | -7.48 |
| Other Special Charges | 0.08 | 0.06 | 10 | - | 7.48 |
| General And Administrative Expense | - | 47.61 | 38.46 | 36.13 | 37.63 |
| Other Gand A | - | 47.61 | 38.46 | 36.13 | 37.63 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Gossamer Bio, Inc.this co. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M | -2.09 |
| - |
| - |
| - |
| - |
| 5.86 |
| -280.5% |
| - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Tevogen Bio Holdings Inc. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| Peer Median | - | -1.58 | 1.06 | -118.2% | -0.47 | |